Learn more about Samphire Neuroscience, our work and women's health.

Read articles written by our team and others below, or join our mailing list to stay up to date.

This shouldn't be new to you

Commonly considered a more severe form of premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD) is a sometimes-disabling condition affecting 3-8% of menstruating people.

Read more...

Build Better: Conversations with Emile Radyte

Currently in semi-stealth mode, Samphire Neuroscience is building their first medical device to treat menstrual symptoms using non-invasive neuromodulation.

Read more...

Investment Notes: Women's Health has been ignored for too long

Read why Ayuh Ventures, a leading longevity venture capital fund, invested in Samphire Neuroscience.

Read more...

Could 'menstrual leave' change the workplace?

More and more companies are answering the call to provide period leave – yet some critics remain sceptical.

Read more...

Women's Pain is Not Pain

This post explores whether women's menstrual pain is a dismissed category of chronic pain.

Read more...

Investment Notes: Samphire Neuroscience

Read why AfterWork Ventures invested in Samphire Neuroscience, a neurotechnology company improving women's health and lifestyles.

Read more...

Our Challenge: The Status Quo

Pain, brain fog and mood challenges around your period. Sound familiar? You’re not alone. In this article we share how we think about the status quo of women's health.

Read more...

Our Approach

We built Samphire Neuroscience because we believe that women deserve at least one solution for the disruptive symptoms most of them experience regularly.

Read more...

Thank you, you are now signed up for the Samphire mailing list. For further queries, email us here.

Oops! Something went wrong while submitting the form.